Quiz|Articles|September 6, 2026
Dermatology Times Spot Test: September 6, 2026
Author(s)Marie Bosslett, Assistant Editor
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
Advertisement
Welcome to Dermatology Times' Spot Test!
Each week, dive into a series of thought-provoking questions designed to test your understanding of essential topics, trends, and breakthroughs in dermatology. This week, we’ll focus on the latest news in
Do you have a set of quiz questions to share? Contact editor Marie Bosslett at
Which mechanism characterizes oral TYK2 inhibitors such as envudeucitinib, socrodeucitinib, and zasocitinib?
What PASI 100 rate did envudeucitinib achieve among continuously treated patients at 48 weeks in the ONWARD3 long-term extension study?
Sonelokimab, evaluated in the phase 3 IZAR-1 trial, targets which cytokines?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement